Kenvue Inc. $KVUE Shares Sold by Plato Investment Management Ltd

Key Points

• Plato Investment Management Ltd reduced its stake in Kenvue Inc. by 26.2% in Q1, now holding 43,165 shares valued at approximately $1,046,000.
• Kenvue increased its quarterly dividend to $0.2075 per share, resulting in an annualized yield of 4.4%, with a payout ratio of 112.16%.
• For Q2, Kenvue reported earnings of $0.29 per share, beating estimates, but experienced a 4.0% decline in revenue compared to the previous year.

Plato Investment Management Ltd lowered its stake in Kenvue Inc. (NYSE:KVUE - Free Report) by 26.2% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 43,165 shares of the company's stock after selling 15,304 shares during the quarter. Plato Investment Management Ltd's holdings in Kenvue were worth $1,046,000 at the end of the most recent quarter.

Several other institutional investors have also bought and sold shares of the stock. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in Kenvue by 15.2% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 14,143,451 shares of the company's stock worth $339,160,000 after purchasing an additional 1,862,258 shares during the period. Empowered Funds LLC lifted its holdings in Kenvue by 26.4% in the first quarter. Empowered Funds LLC now owns 224,937 shares of the company's stock worth $5,394,000 after purchasing an additional 46,928 shares during the period. MBB Public Markets I LLC acquired a new stake in Kenvue in the first quarter worth about $341,000. Adalta Capital Management LLC acquired a new stake in Kenvue in the first quarter worth about $192,000. Finally, Meiji Yasuda Asset Management Co Ltd. lifted its holdings in Kenvue by 2.1% in the first quarter. Meiji Yasuda Asset Management Co Ltd. now owns 66,736 shares of the company's stock worth $1,600,000 after purchasing an additional 1,360 shares during the period. Institutional investors and hedge funds own 97.64% of the company's stock.

Kenvue Price Performance

Shares of Kenvue stock opened at $18.84 on Friday. The company has a current ratio of 0.98, a quick ratio of 0.68 and a debt-to-equity ratio of 0.66. The company's 50-day moving average price is $21.18 and its two-hundred day moving average price is $22.27. Kenvue Inc. has a 52 week low of $17.15 and a 52 week high of $25.17. The stock has a market cap of $36.16 billion, a PE ratio of 25.46, a price-to-earnings-growth ratio of 2.65 and a beta of 0.83.

Kenvue (NYSE:KVUE - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The company reported $0.29 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.28 by $0.01. The firm had revenue of $3.84 billion for the quarter, compared to the consensus estimate of $3.94 billion. Kenvue had a return on equity of 20.06% and a net margin of 9.37%.The business's revenue for the quarter was down 4.0% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.32 EPS. Kenvue has set its FY 2025 guidance at 1.000-1.050 EPS. As a group, sell-side analysts anticipate that Kenvue Inc. will post 1.14 EPS for the current fiscal year.

Kenvue Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, August 27th. Shareholders of record on Wednesday, August 13th were issued a dividend of $0.2075 per share. This represents a $0.83 annualized dividend and a yield of 4.4%. The ex-dividend date was Wednesday, August 13th. This is a boost from Kenvue's previous quarterly dividend of $0.21. Kenvue's dividend payout ratio is presently 112.16%.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on the stock. Zacks Research raised shares of Kenvue to a "strong sell" rating in a report on Monday, August 11th. Barclays reduced their price objective on shares of Kenvue from $23.00 to $22.00 and set an "equal weight" rating for the company in a report on Tuesday, July 15th. JPMorgan Chase & Co. dropped their price target on shares of Kenvue from $27.00 to $26.00 and set an "overweight" rating on the stock in a research report on Friday, July 25th. Citigroup dropped their price target on shares of Kenvue from $24.50 to $22.00 and set a "neutral" rating on the stock in a research report on Tuesday, July 15th. Finally, Evercore ISI dropped their price target on shares of Kenvue from $25.00 to $23.00 and set an "in-line" rating on the stock in a research report on Monday. Five research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, Kenvue currently has an average rating of "Hold" and an average target price of $24.21.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.